Prion protein (PrP) prevents Bcl-2-associated protein X (Bax)-mediated cell death, but the step at which PrP inhibits is not known. We first show that PrP is very specific for Bax and cannot prevent Bak (Bcl-2 antagonist killer 1)-, tBid-, staurosporine-or thapsigargin-mediated cell death. As Bax activation involves Bax conformational change, mitochondrial translocation, cytochrome c release and caspase activation, we investigated which of these events was inhibited by PrP. PrP inhibits Bax conformational change, cytochrome c release and cell death in human primary neurons and MCF-7 cells. Serum deprivation-induced Bax conformational change is more rapid in PrP-null cells. PrP does not prevent active caspase-mediated cell death. PrP does not colocalize with Bax in normal or apoptotic primary neurons and cannot prevent Bax-mediated cytochrome c release in a mitochondrial cell-free system. We conclude that PrP protects against Bax-mediated cell death by preventing the Bax proapoptotic conformational change that occurs initially in Bax activation.
Introduction
While the nature of infectious prion protein (PrP) has been intensively investigated, the function of normal cellular PrP is yet to be entirely resolved. In many instances, PrP acts as a neuroprotective or survival protein. PrP-null cells are more susceptible to serum deprivation and oxidative stress than PrP-expressing cells. 1, 2 PrP prevents anisomycin-mediated cell death in the neuroblastic layer of mouse retinal explants, 3, 4 Doppel-and N-terminally truncated PrP-induced neurodegeneration in mice, 5, 6 and tumor necrosis factor a (TNFa)-induced apoptosis in MCF-7 cells. 7 We have shown that both wild-type and cytosolic PrP completely inhibit Bcl-2-associated protein X (Bax)-mediated cell death in human neurons in primary cultures. 8, 9 However, whether PrP inhibits upstream or downstream of Bax activation is not known.
Bax is a major proapoptotic protein of neuronal cells. 10, 11 In normal conditions, Bax is monomeric and is either cytosolic or loosely attached to the mitochondrial outer membrane. 12 Following a proapoptotic stimulus, Bax translocates from the cytosol to the mitochondria, changes conformation to expose its N-terminal domain and oligomerizes at the mitochondria. These events, conveniently labeled Bax activation, result in the release of mitochondrial apoptogenic proteins including cytochrome c, endonuclease G, Smac/Siablo, Htr2/Omi and apoptosis-inducing factor (AIF), which activate caspasedependent and -independent apoptosis pathways. 13 Bcl-2, Bcl-xL, Ku70, Bax inhibitor 1 (BI-1), bifunctional apoptosis regulator (BAR), humanin, Hsp70, aA-and aB-crystallins and nonphosphorylated 14-3-3 protein have been identified as natural Bax inhibitors. [14] [15] [16] [17] [18] [19] [20] [21] [22] All of these except BAR and BI-1 are cytosolic and directly interact with Bax. All, except Bcl-2, and BAR, have been shown to prevent Bax translocation to the mitochondria. Bcl-2, Bcl-xL, BI-1, and Ku70 proteins have also been shown to prevent Bax proapoptotic conformational change. BAR and BI-1 are endoplasmic reticulum (ER) transmembrane proteins that interact with Bcl-2 but not Bax, and their effect on Bax conformational change or translocation is unclear at this time.
In this study, we investigate the step at which PrP inhibits Bax-mediated cell death in human neurons. We find that PrP protection is fairly specific to Bax since PrP does not protect against Bcl-2 antagonist killer 1-(Bak), truncated Bid-(tBid), staurosporine-(STS) and thapsigargin-mediated cell death.
Using subcellular fractionation and gel filtration chromatography, we confirm that Bax undergoes a conformational change and oligomerization in apoptotic primary human neurons. In parallel with inhibition of cell death, PrP inhibits 6A7 antibodypositive Bax conformational change in human neurons and in breast cancer MCF-7 cells microinjected or transfected with Bax or EGFP-Bax cDNA overexpression constructs to simulate specific Bax proapoptotic activation. Furthermore, Bax conformational change occurs more rapidly in serumdeprived immortalized hippocampal PrP-null cells than in the PrP-expressing counterparts. PrP does not prevent EGFP-Bax mitochondrial localization in human neurons, but partially inhibits mitochondrial EGFP-Bax translocation in MCF-7 cells. PrP prevents Bax-mediated cytochrome c release in neurons and MCF-7 cells. However, recombinant PrP (R-PrP), unlike Bcl-2, cannot prevent Bax-mediated cytochrome c release from purified mitochondria in a cell-free assay. In addition, PrP does not prevent human neuronal cell death after the activation of the effector caspase. We conclude that PrP prevents Bax-mediated cell death by inhibiting the very first step of Bax proapoptotic activation, and that PrP does not function exactly like Bcl-2 despite strong functional similarities with Bcl-2. These results unexpectedly add PrP to the growing list of Bax inhibitors and caution against the ablation of the prnp gene as a method to eradicate infectious PrP diseases.
Results

PrP prevents Bax but not Bak-or tBid-mediated cell death in human neurons and MCF-7 cells
We have previously shown that PrP prevents Bax-mediated cell death in human neurons. 8, 9 To assess the specificity of this neuroprotective role for PrP against Bax, we investigated if PrP could prevent cell death due to Bak, another proapoptotic member of the Bcl-2 family that is closely related to Bax. 23, 24 PrP does not prevent EGFP-Bak-mediated cell death in human neurons (Figure 1a ). To determine if the antiBax function of PrP is specific to human neurons, we studied MCF-7 cells, where PrP was found to protect against TNFainduced cell death. 7 PrP maintains its protection against Baxmediated cell death in the MCF-7 cells as does Bcl-2, allowing us to use these as a model cell line to study the effects of PrP (Figure 1b) . We then investigated if PrP could prevent cell death mediated by tBid, a BH3-only proapoptotic Bcl-2 protein that activates both Bax and Bak. 25, 26 In human neurons, PrP does not prevent tBid-DsRed2-mediated cell death (Figure 1c ), but partially protects MCF-7 cells (Figure 1d ). This partial protection can be explained by the fact that EGFPBak does not cause rapid cell death in MCF-7 cells (Figure 1e ). Indeed, PrP does not protect anymore in MCF-7 cells 48 or 96 h after tBid-DsRed2 transfection (Figure 1d ). Together, these results show that PrP protection is fairly specific to Bax, but can occur in both terminally differentiated and in cycling cell types.
Bax undergoes mitochondrial translocation, oligomerization and induces the release of cytochrome c in STS-induced apoptotic human neurons Bax-mediated cell death occurs through a series of wellcontrolled steps, which include a conformational change that exposes the N-and C-termini of Bax, oligomerization of Bax and translocation from cytosol to the mitochondria, resulting in the release of cytochrome c and caspase activation. Inhibition of any of these events would result in protection against Baxmediated cell death. We set out to investigate which of these steps PrP inhibited. We first verified the series of events involved in Bax-mediated cell death in primary cultures of human neurons because mechanisms of cell death are sometimes different in this cell type. [27] [28] [29] In normal nonapoptotic conditions, Bax is more abundant in the cytosol of human neurons, but a certain amount copurifies with mitochondria ( Figure 2a and c) . As in other cells, cytosolic monomeric Bax translocates to the mitochondria (Figure 2a) , undergoes the 6A7 antibody-positive conformational change (Figure 2b) , 30 oligomerizes at the mitochondria (Figure 2c ), 31 and induces the release of cytochrome c (Figure 2d (Figure 3a) . These results show that Bax activation occurs normally in apoptotic human neurons.
PrP prevents Bax conformational change in neurons
To investigate if PrP can prevent Bax conformational change, neurons were microinjected with human Bax cDNA expressed under the strong cytomegaloviral promoter to induce specific Bax-mediated cell death, 8 and immunostained with the 2D2 or 6A7 antibodies that detect total Bax and apoptotic Bax, respectively. The 2D2 antibody detects Bax in all neurons (Figure 3a) . In contrast, the 6A7 proapoptotic Bax antibody immunostains Bax-injected neurons only, indicating conformational change following overexpression of Bax. Neurons coinjected with Bax and PrP or Bax and Bcl-2 cDNAs fail to show immunoreactivity to 6A7, while 2D2 immunoreactivity is preserved. A higher magnification view of the microinjected cells shows that 6A7-and 2D2-positive Bax is abundantly cytosolic (Figure 3a lower panel presented as merge of figure insets) as seen in other cell types. 32 As the Dextran Texas Red (DTR) comicroinjected to mark the injected cells aggregates, it is very difficult to colocalize Bax with specific organelles, but the punctate appearance of some of the immunostaining indicates a possible mitochondrial localization. We conclude from this experiment that, like Bcl-2, PrP prevents Bax conformational proapoptotic change in primary human neurons.
Human neurons are difficult to transfect and microinjections limit the studies to single-cell analysis. Therefore, we tested the ability of endogenous PrP to prevent apoptotic Bax 1 Nonidet P-40 (NP-40) is used as a positive control for 6A7 because it artificially induces Bax conformational change. 30 The 6A7 antibody immunoprecipitates slightly less Bax in serum-deprived neurons lysed with NP-40 detergent, indicating that total levels of Bax decrease 
PrP prevents Bax-mediated cytochrome c release in human neurons and MCF-7 cells
Bcl-2 has been shown to prevent Bax-mediated cell death without affecting cytochrome c release in transfected HEK293T cells. 33 To determine if PrP prevents Bax-mediated mitochondrial cytochrome c release, human neurons were transfected with EGFP-Bax cDNA and immunostained with anti-cytochrome c antibodies (Figure 4a and Supplementary Figure S1 ). Neurons transfected with EGFP alone display diffuse fluorescence consistent with cytosolic and nuclear localization of EGFP (Figure 4a ). EGFP-Bax localizes mainly at the mitochondria and induces the loss of mitochondrial cytochrome c immunostaining (Figure 4a ). Diffuse cytosolic cytochrome c is generally not detected in neurons. 34, 35 However, when PrP or Bcl-2 is cotransfected with EGFPBax, cytochrome c is easily detected (Figure 4a 
PrP inhibits EGFP-Bax mitochondrial localization in MCF-7 cells but not in human neurons
In human neurons, EGFP-Bax remains at the mitochondria in neurons cotransfected with PrP or Bcl-2 cDNAs (Figure 4a) . Consequently, EGFP-Bax and cytochrome c colocalize at the mitochondria. However, unlike our observations in neurons, EGFP-Bax accumulates in the cytosol in 60% of the MCF-7 cells cotransfected with PrP or Bcl2 cDNAs, and localizes at the mitochondria in 40% of the cells (Figure 4b ). One possible explanation for this finding is that EGFP-Bax is expressed or accumulates less in human neurons and that there are not enough copies of EGFP to be detected in the cytosol. However, it is also possible that in human neurons, Bax remains loosely attached to mitochondria as observed in subcellular fractionation studies (Figures 2a and 7a) .
PrP does not inhibit cell death after the activation of caspases
To determine if PrP can prevent caspase-mediated cell death in the absence of the upstream activation of Bax, neurons were coinjected with the active form of caspase-6 previously shown to be the effector apoptotic caspase in human neurons. 28, 36 PrP does not prevent caspase-6-mediated cell death ( Figure 5 ). Therefore, in the mitochondrial apoptotic pathway, PrP antiapoptotic activity is limited to Bax conformational change. Figure 1a) and by serum deprivation. 1 To assess if PrP may protect against other proapoptotic insults, we investigated the ability of PrP to prevent kinase inhibitor STS and ER thapsigarginmediated apoptosis. PrP cannot prevent STS-induced cell death in MCF-7 cells (Figure 6a ) despite being able to inhibit Bax conformational change (Figure 6b) . Similarly, PrP does not prevent cell death induced by the ER stress, thapsigargin (Figure 6c ). This could be explained by the fact that STS and thapsigargin activate Bax and Bak 37 and PrP cannot prevent Bak-mediated cell death. However, we know that Bak kills MCF-7 cells very slowly (Figure 1e ), so Bak cannot account for cell death in the STS-or thapsigargin-treated cells since they were treated for less than 24 h. Therefore, these two drugs likely induce other pathways of cell death against which PrP is inefficient. 
PrP does not inhibit Bax directly
Previously, it has been shown that PrP accumulates in the cytosol of cells treated with proteasomal inhibitors. 9, [38] [39] [40] [41] Furthermore, some neurons seem to only have cytosolic PrP. 42 Since the accumulation of PrP in the cytosol provides an opportunity for PrP to interact directly with Bax as shown with other anti-Bax proteins, the subcellular localization of PrP was compared in normal and apoptotic neurons to assess if cytosolic PrP increases under apoptotic conditions and could colocalize with Bax. PrP is found mostly in the microsomal and in the crude mitochondrial fractions (Figure 7a) . However, further purification of the mitochondria, characterized by an increase in mitochondrial Hsp70, showed that unlike Bax and APP, recently shown to have a mitochondrial localization signal, 43 PrP does not copurify with the mitochondria. In contrast, Bax is present mostly in mitochondria and the cytosol and is absent from the microsomes. Therefore, under apoptotic conditions, PrP does not accumulate in the cytosol and does not have this opportunity to interact with Bax.
Despite the lack of increased cytosolic PrP in apoptotic conditions, we must still consider that PrP could be found under some condition in the cytosol and thus could have access to Bax. Therefore, in some conditions, cytosolic PrP might directly interact with Bax to inhibit its conformational change. To assess if PrP can directly inhibit Bax activation in a cell-free system, the effect of R-PrP on recombinant tBid-and Bax-induced cytochrome c release in isolated mitochondria was examined. Recombinant monomeric Bax and tBid alone do not induce the release of cytochrome c, as shown previously. 44 Cytochrome c release occurs from mitochondria treated with Bax and tBid (Figure7b and Roucou et al. 44 ). As expected, Bcl-2 prevents cytochrome c release. However, PrP is not able to prevent Bax-mediated cytochrome c release in these conditions. Preincubation of Bax with PrP did not have any effect either. We conclude from these experiments that, unlike Bcl-2, but like BAR and BI-1, PrP probably cannot prevent Bax-mediated cell death by directly interacting with Bax.
Discussion
Previously, we have shown that PrP protects human neurons in primary cultures against Bax-mediated cell death detected by TUNEL-positive DNA fragmentation. 8, 9 However, the question of whether PrP inhibits cell death upstream or downstream of Bax remained to be answered. Bax-mediated apoptosis involves a complex series of events that initially includes the conformational change of Bax into a proapoptotic protein and Bax translocation from the cytosol to the mitochondria followed by an increase of mitochondrial permeability to release apoptogenic factors, cytochrome c, AIF and endonuclease G. In this paper, we investigated the level at which PrP inhibits Bax-mediated cell death. We found that PrP prevents the proapoptotic conformational change of Bax, the most distal step in Bax activation. Ectopic expression of PrP prevents the proapoptotic conformational change of Bax activation in human neurons and in MCF-7 cells triggered to undergo Bax-mediated apoptosis by overexpressing Bax or EGFP-Bax in these cells. Furthermore, Bax proapoptotic conformational change occurs more rapidly in serumdeprived cells that lack endogenous expression of PrP. Bcl-2 has been shown to prevent Bax-mediated cell death without affecting cytochrome c release in transfected HEK293T. 33 Therefore, it was important to determine if PrP would inhibit cell death after cytochrome c release. Our results indicate that this is not the case. We show that when PrP prevents Baxmediated cell death, cytochrome c is always retained in the mitochondria. In addition, PrP cannot prevent caspase-6-mediated cell death when the caspase is directly microinjected into the cytosol of human neurons. These results indicate that PrP is a potent Bax inhibitor that acts at the very first step of Bax activation and unexpectedly add PrP to the growing list of Bax inhibitors.
It is not clear at this time whether PrP acts directly or indirectly on Bax. Several inhibitors of Bax like humanin, Ku70, 14-3-3, crystallins and Hsp70 directly interact with Bax in the cytosol and prevent Bax translocation to the mitochondria. [16] [17] [18] [19] [20] However, while a small amount of normal PrP is retrotranslocated from the ER to the cytosol 9, 38, 39 and this PrP could directly interact with and prevent Bax conformational change, most of the PrP is present in the secretory pathway and attached at the cell surface through its glycophosphatidyl inositol anchor. We have shown here that the subcellular distribution of PrP does not change in serum-deprived induced apoptosis of human primary neurons. Furthermore, R-PrP does not prevent Bax and tBid-mediated cytochrome c release from purified mitochondria in a cell-free system (Figure 7b) . Therefore, unless PrP also needs to be in a specific conformation to inhibit Bax, it is unlikely that PrP acts directly by interacting with Bax.
Another possibility is that PrP acts through Bcl-2 since, like Bcl-2, 32 PrP prevents Bax conformational change (Figure 2 ), Bax-mediated cell death 8, 9 and interacts with Bcl-2. 45 2,47 PrP and Bcl-2 do not prevent EGFP-Bax translocation to the mitochondria in human neurons and only partially prevent EGFP-Bax translocation in MCF-7 cells, but both Bcl-2 and PrP prevent Bax-induced cytochrome c release (Figure 4a and b) . 48 Bcl-2 also does not have to be localized at the mitochondria to inhibit Bax as ER-targeted Bcl-2 is also able to prevent Bax activation. 49 However, unlike Bcl-2, PrP cannot protect against Bak-or tBid-mediated cell death, [50] [51] [52] [53] prevent tBid-and Bax-mediated cytochrome c release in a cell-free system (Figure 7b ) and does not prevent Bax-mediated cell death in all cell types. 54 Furthermore, PrP is localized mostly in the lumen of the ER rather than attached on the cytoplasmic surface of the ER via a transmembrane Cterminal domain like Bcl-2. Therefore, PrP probably acts differently than Bcl-2 in preventing Bax conformational change.
Another possibility is that PrP functions like BAR and BI-1. Both of these Bax inhibitors are localized in the ER as transmembrane proteins.
14,15 BAR and BI-1 do not directly interact with Bax, but they do interact with Bcl-2 and Bcl-x. BAR also interacts with caspase-8 and may function as a bridge between Bcl-2 and caspase-8.
14,55 BI-1 inhibits thapsigargin-mediated cell death in mouse embryonic fibroblasts or the HT1080 human fibrosarcoma cell line by preventing calcium release and Bax activation. 22 In contrast, PrP does not prevent thapsigargin-mediated cell death in MCF-7 cells (Figure 6c ), indicating that PrP is not working through BI-1. However, these two Bax inhibitors control Bax indirectly, a mechanism that is most consistent with PrP's localization in the secretory pathway.
A major difference between PrP and other Bax inhibitors is that PrP is quite specific to Bax-mediated cell death. PrP protection occurs only with Bax or EGFP-Bax overexpression, two insults that directly activate the Bax proapoptotic pathway. PrP cannot prevent Bak-, tBid-, STS-or thapsigarginmediated cell death. These last three insults are known to activate Bak in some cell lines, 37, 53, 56 and this could explain why PrP cannot prevent cell death. However, Bak does not appear to play a major role in MCF-7 cell death until after 24 h of the insult, indicating that STS and thapsigargin likely activate other cell death pathways that PrP cannot prevent.
To find the underlying molecular mechanism by which PrP prevents Bax conformational change will not be easy. Although it is clearly established that Bax conformational change involves a structural rearrangement in the N-and Cterminal domains of the protein, little is known about how Bax is activated. Some have reported that a decrease in cellular cytosolic pH, interaction of Bax with membranes and oligomerization result in Bax proapoptotic conformational change. [57] [58] [59] [60] [61] Which of these potential mechanisms is targeted by the well-known Bax inhibitor, Bcl-2, have been under intense investigations for years, but have not yet been elucidated.
In summary, we have shown that PrP prevents Baxmediated cell death by inhibiting Bax proapoptotic conformational change, but not Bax translocation, in human neurons and MCF-7 cells. This is the first example, other than Bcl-2, in which a Bax inhibitor does not prevent Bax translocation to the mitochondria, but clearly inhibits Bax proapoptotic conformational change and cell death. These results unexpectedly add PrP to the growing list of Bax inhibitors and imply that care need to be taken if ablation of PrP as a method to prevent infectious prion diseases is to be considered as a therapy. It is possible that this significant neuroprotective role of PrP may be very important to protect the brain against pathological conditions.
Materials and Methods
Antibodies
Monoclonal 2D2, 6A7 and polyclonal N20 anti-Bax antibodies were purchased from Trevigen (Gaithersburg, MD, USA), BD Pharmingen (Mississauga, ON, Canada) and Santa Cruz Biotechnology (Santa Cruz, CA, USA), respectively. Monoclonal anti-mitochondrial Hsp70 (mtHsp70; clone JG1), anti-b-actin (clone AC-15) and monoclonal antibodies recognizing either the native (clone 6H2.B4 for immunostaining) or the denatured (clone 7H8.2C12 for Western blots) forms of cytochrome c were purchased from Affinity BioReagents (Golden, CO, USA), Sigma (Oakville, ON, Canada), Chemicon (Temecula, CA, USA) and BD Pharmingen (Mississauga, ON, Canada), respectively. The APP antibody 22C11 was purchased from Roche Diagnostics (Montreal, QC, Canada). Fluorescein-5-isothiocyanate (FITC)-conjugated sheep affinity-purified antibodies to mouse IgG (Bax immunostaining) and tetramethylrhodamine-5 (and-6)-isothiocyanate-conjugated goat IgG fraction to mouse IgG (for cytochrome c immunostaining) were purchased from Rockland Immunochemicals (Bridgeport, NJ, USA).
Clones
Cloning of EGFP, EGFP-Bax, PrP and Bcl-2 in pCep4b (Invitrogen, Burlington, ON, Canada) was described previously. 8, 9 Human Bak was amplified by PCR amplification from the pcDNA3. 
Cell culture and treatments
Human primary neurons were cultured as described. 27, 62 Hippocampal HW3-5 and HpL3-4 cell lines established from PrP þ / þ and PrP À/À mice, respectively, were a kind gift from Dr. T Onodera (University of Tokyo, Japan) and were serum-deprived as described previously. 
Transfections
Human neurons were plated at a cell density of 3 Â 10 6 cells/ml onto poly-D-lysine-(20 mg/ml; Sigma, St. Louis, MI, USA) and laminin-(10 mg/ml; Sigma) coated glass coverslips in 24-well plates. Neurons were transfected using 3.3 ml ExGen 500 and 1.6 mg DNA per 150 000 cells according to the manufacturer's protocol (MBI; Burlington, ON, Canada). Alternatively, neurons were transfected with 1 mg DNA/shot using the Helios Gene Gun System from BioRad (Mississauga, ON, Canada) at a shooting pressure of 220 psi according to the manufacturer's protocol. Briefly, transfection cartridges were prepared with 0.033 mg DNA for a single construct and three times more of a second construct (0.099 mg), 4.2 mg gold microcarrier beads in 0.1 ml calcium chloride 1 M and 0.1 ml 0.05 M spermidine. The beads were centrifuged and washed three times with 100% ethanol and resuspended in 2 ml 100% ethanol before coating the cartridges. The cartridges had a microcarrier loading quantity of 0.125 mg gold/shot and a DNA loading ratio of 8 mg DNA/mg gold. MCF-7 cells of 90% confluence were transfected with 4 mg DNA using Lipofectamine 2000 (Invitrogen, Burlington, ON, Canada). MCF-7 cells at 50% confluence were transfected with the Helios Gene Gun System as described above for human neurons. When transfecting two constructs, MCF7 cells were transfected with a 1 : 3 ratio of pCep4b-EGFPBax : pCep4b, or pCep4b-EGFP-Bax : pCep4b-PrP, or pCep4b-EGFPBax : pCep4b-Bcl-2. When transfecting three constructs, MCF-7 cells were transfected with a 1 : 6 ratio of pCep4b-EGFP : pCep4b, or a 1 : 2 : 4 ratio of pCep4b-EGFP : pCep4b-Bax : pCep4b-, pCep4b-EGFP : pCep4b-Bax : pCep4b-PrP or pCep4b-EGFP : pCep4b-Bax : pCep4b-Bcl-2.
Microinjection
Microinjections were performed as described. 8, 63, 28 R-Csp6 was prepared in caspase-6 active buffer containing 20 mM piperazine-N,N 0 -bis-(2-ethanesulfonic acid) (PIPES), 100 mM NaCl, 10 mM dithiothreitol (DTT), 1 mM EDTA, 0. 
Cell death measurements
Microinjected neuronal cell death was carried out as described previously. 28 Briefly, DTR (Cedarlane, Hornby, ON, Canada) was coinjected as a fluorescent marker to detect injected neurons. Cell death was assessed 48 h postmicroinjection by TUNEL according to the manufacturer's protocol (In Situ Cell Death Detection Kit (A, P), Roche Applied Science, Laval, QC, Canada). Transfected human neuronal cell death was also determined by TUNEL using the TMR-red for cells transfected with EGFP-expressing constructs and fluorescein-labeled nucleotides for the detection of cells transfected with DsRed2-expressing constructs. The percentage of neuronal apoptosis was determined by the ratio of the number of DTR and TUNEL double-positive neurons over the total number of DTR-positive neurons. Cell death in MCF7 cells was measured by counting EGFP-positive cells displaying condensed chromatin stained with 1 mg/ml Hoescht 33342 versus total number of EGFP-positive cells.
Immunoprecipitation
Proteins were extracted in NP-40 or CHAPS lysis buffer (150 mM sodium chloride, 50 mM Tris-HCl (pH 8.0), 1% NP-40 or 1% CHAPS), and Bax was immunoprecipitated with monoclonal 2D2 or 6A7 antibodies (1/100 dilution). 64 Bax was detected by Western blotting with polyclonal N20 antibody (1/3000 dilution).
Subcellular fractionation, Bax oligomerization and cytochrome c release
Cells were harvested in PBS and homogenized with a Dounce homogenizer in buffer A (8% sucrose, 20 mM Tricine, 1 mM EDTA, pH 7.8) supplemented with complete protease inhibitor mixture (Roche Applied Science, Laval, QC, Canada). Subcellular fractionation was performed as described. 31 Mitochondrial proteins were fractionated on a Superdex 200 column (16/60) as described previously. 31, 44 The presence of cytochrome c, mtHsp70 and b-actin in mitochondria-containing heavy membrane fraction and cytosol was analyzed by western Blotting with monoclonal antibodies (1/1000 dilution).
Immunofluorescence
Cells were fixed for 20 min with 4% paraformaldehyde and 4% sucrose 24 h after transfection (cytochrome c release in neurons and MCF-7 cells) or microinjection (Bax conformational change in neurons). Cells were permeabilized with either 0.2% CHAPS in PBS for 2 min (Bax immunostaining with 2D2 or 6A7) or with 0.2% Triton X-100 in PBS for 10 min (cytochrome c immunostaining with monoclonal 6H2.B4) at room temperature. After washing, the cells were incubated overnight with monoclonal antibodies (1 : 100 dilution in PBS þ 10% normal goat serum), washed twice in PBS and detected with secondary anti-mouse antibodies (1/100 dilution). Fluorescein-5-isothiocyanate-and tetramethylrhodamine-5-isothiocyanate-conjugated secondary antibodies were used to detect Bax and cytochrome c, respectively. In the last wash, 1 mg/ml of Hoescht 33342 was added to stain cellular nuclei. Coverslips were mounted on with the SlowFade Light Antifade Kit (Molecular Probes, Eugene, OR, USA) and observed by conventional epifluorescence microscopy using a Nikon eclipse TE2000-U microscope (Mississauga, ON, Canada). Images were acquired with an Orca-ER CCD camera (Improvision, Guelph, ON, Canada), Openlab (Improvision, Guelph, ON, Canada) and Adobe Photoshop 6.0 (Ottawa, ON, Canada) softwares.
Cell-free mitochondrial release of cytochrome c
Mitochondria were isolated from mouse liver and purified in a sucrose gradient as described previously.
65 Mitochondria (0.1 mg) were added to 0.1 ml of release buffer (210 mM mannitol, 70 mM sucrose, 10 mM Hepes : NaOH, pH 7.4, 0.5 mM EGTA, 5 mM succinate, 4 mM MgCl 2 and 5 mM Na 2 HPO 4 ). Recombinant monomeric full-length Bax (R-Bax, 100 nM) was added in the absence or presence of 5 nM recombinant tBid (R-tBid), 600 nM recombinant Bcl-2 (R-Bcl-2) or 600 nM R-PrP, and the mitochondria were incubated for 30 min at 301C. Mitochondria were centrifuged for 10 min at 10 000 Â g. The presence of cytochrome c was analyzed in the pellet by Western blotting using monoclonal 7H8.2C12 antibodies. R-Bax and R-tBid were obtained from Professor Jean-Claude Martinou (University of Geneva, Geneva, Switzerland). R-PrP was a gift from Dr. Witold Surewicz (Case Western University, Cleveland, OH, USA). R-Bcl-2 was purchased from Cedarlane Lab. Ltd (Hornby, ON, Canada).
Statistical evaluation
Statistical differences were analyzed with analysis of variance followed by post hoc Scheffé's test using StatView (SAS Institute Inc., Cary, NC, USA). A Po0.05 was taken as a significant difference. 
